A Bengaluru-based biotech startup is developing a breakthrough solution for corneal damage. Pandorum Technologies’ “Liquid Cornea” could reshape how doctors treat vision loss in the future.

Photobiomodulation with the Valeda light delivery system was authorized in November 2024, and we have been treating patients with it since summer 2025.It seems too simple to be true that we could ...

More than 10,000 Americans who suffer from chronic liver disease are on a waitlist for a liver transplant, but there are not ...

Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with ...

Six planets, Mercury, Venus, Neptune, Saturn, Uranus, and Jupiter, will be visible, according to NASA. Seeing a parade of six or even seven planets is rare. Of the six, four will be visible to the ...

Here’s something big: scientists in China have actually reversed type 2 diabetes using stem-cell therapy. It’s a major step forward, not just ...

Hugo Powell was born weighing 6lb 13oz in December at Queen Charlotte's and Chelsea Hospital after his mother Grace Bell received a womb transplant from a deceased donor.

In a groundbreaking procedure, Dr Agarwals Eye Hospital restored sight to a gynaecologist blind in both eyes using advanced surgical techniques. The pioneering combination of intraocular lens ...

Data from cell phones entering the area of Nancy Guthrie's home around the time of her disappearance could help investigators determine a list of suspects, according to a digital forensics expert. “I ...

Actor-singer Bijou Phillips has been hospitalized for a second kidney transplant and is urgently seeking a donor, a rep tells Variety. A previous transplant, in 2017, was unsuccessful; the rep says ...

The Breakthrough T1D San Francisco Gala returns for its 27th year, bringing the T1D community together for "A Magical Night Beneath the Cherry Blossoms" at the iconic San Francisco City Hall. This ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...